Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Other Non-Current Liabilities: 2012-2024

Historic Other Non-Current Liabilities for Ironwood Pharmaceuticals (IRWD) over the last 11 years, with Dec 2024 value amounting to $17.1 million.

  • Ironwood Pharmaceuticals' Other Non-Current Liabilities fell 44.14% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.2 million, marking a year-over-year decrease of 44.14%. This contributed to the annual value of $17.1 million for FY2024, which is 39.80% down from last year.
  • Per Ironwood Pharmaceuticals' latest filing, its Other Non-Current Liabilities stood at $17.1 million for FY2024, which was down 39.80% from $28.4 million recorded in FY2023.
  • In the past 5 years, Ironwood Pharmaceuticals' Other Non-Current Liabilities registered a high of $28.4 million during FY2023, and its lowest value of $1.8 million during FY2020.
  • Its 3-year average for Other Non-Current Liabilities is $18.4 million, with a median of $17.1 million in 2024.
  • Its Other Non-Current Liabilities has fluctuated over the past 5 years, first surged by 190.96% in 2023, then tumbled by 39.80% in 2024.
  • Yearly analysis of 5 years shows Ironwood Pharmaceuticals' Other Non-Current Liabilities stood at $1.8 million in 2020, then surged by 98.58% to $3.5 million in 2021, then surged by 178.95% to $9.8 million in 2022, then soared by 190.96% to $28.4 million in 2023, then crashed by 39.80% to $17.1 million in 2024.